UCB to acquire Zogenix

/PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered...

Related Keywords

Japan ,California ,United States ,Emeryville ,Brussels ,Bruxelles Capitale ,Belgium ,Dravetc Dravet ,Charl Van Zyl ,Tevard Biosciences ,Stephenj Farr ,Twitter ,Zogenix Inc ,Barclays ,Zinc Merger Sub Inc ,Committee For Medicinal Products Human Use ,National Institute Of Neurological Disorders ,Neurology Head Of Europe International ,Statement Of Zogenix Inc ,Drug Administration ,Latham Watkins ,Lazard ,Covington Burling ,Exchange Commission ,Zogenix Press ,European Medicines Agency ,Euronext ,New Drug Application ,Priority Review ,Executive Vice President ,International Markets ,Chief Executive Officer ,Zinc Merger Sub ,Capital Markets Call ,Prescribing Information ,Boxed Warning ,Euronext Brussels ,Information About ,Recommendation Statement ,Information Agent ,Looking Statement ,Private Securities Litigation Reform Act ,New Therapy ,Medicinal Products ,Human Use ,Zogenix Submits New Drug Application ,Epileptic Seizures Associated ,Zogenix Pipeline ,Zogenix Submits Type ,Seizures Associated ,Supplemental New Drug Application ,Lennox Gastaut Syndrome ,Core Dravet Syndrome ,Med Child ,Dravet Syndrome ,National Institute ,Neurological Disorders ,Lennox Gastaut Syndrome Information ,Last Accessed Jan ,Fintepla Summary ,Ucb And Zogenix ,